Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | CCKBR | P32239 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645694 | 1.00 | SCN9A (0.51) | SCN9AEPHX2XIAPCCKBR | |
| SCHEMBL644741 | 0.89 | SCN9A (0.47) | SCN9AEPHX2XIAP | |
| SCHEMBL12522580 | 0.88 | SCN9A (0.49) | SCN9AEPHX2XIAPCCKBR | |
| SCHEMBL10263272 | 0.88 | SCN9A (0.46) | SCN9AEPHX2XIAPCCKBR | |
| SCHEMBL5619776 | 0.86 | SCN9A (0.51) | SCN9AEPHX2XIAP | |
| SCHEMBL5619770 | 0.86 | SCN9A (0.51) | SCN9AEPHX2XIAP | |
| SCHEMBL13310781 | 0.86 | SCN9A (0.53) | SCN9AEPHX2XIAP | |
| SCHEMBL4427298 | 0.86 | SCN9A (0.53) | SCN9AEPHX2XIAP | |
| SCHEMBL4427306 | 0.86 | SCN9A (0.53) | SCN9AEPHX2XIAP | |
| SCHEMBL13139827 | 0.85 | XIAP (0.47) | SCN9AXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2019-03-14 | — | — | US | disclosed |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2018-09-25 | — | — | US | disclosed |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2015-02-19 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-6008217-A | AN ENZYME INHIBITOR AGAINST INTERLEUKIN-1B, FOR TREATING APOPTOSIS-MEDIATED DISEASES, INCLUDING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, PROLIFERATIVE DISORDERS, INFECTIOUS DISEASES, AND DEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-28 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5874424-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | SCN9A 2305/4885EPHX2 1830/4885XIAP 257/4885 |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | SCN9A 2626/4885EPHX2 2332/4885XIAP 3342/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | SCN9A 1346/4885EPHX2 419/4885XIAP 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.